Paul Thomas Spellman

Paul Thomas Spellman is a Professor in both Medicine and Human Genetics at the University of California Los Angeles (UCLA). His research program focuses on applying genomic and computational technologies to improve human health, with particular emphasis on improving outcomes for cancer patients. He maintains an active laboratory that works across the entire translational spectrum from technology development to clinical implementation.

Dr. Spellman received his education from prestigious institutions: SB in Biology from MIT (1995), PhD in Genetics from Stanford University School of Medicine (2000), and postdoctoral training in Gene Regulation/Genomics from UC Berkeley (2003). This strong foundation in both basic and clinical sciences has positioned him at the forefront of cancer genomics research.

His research interests span Cancer, Genetics, Genomics, Precision Medicine, and Computational Biology. Dr. Spellman's work bridges fundamental genomic science with clinical applications, particularly in cancer genomics. His laboratory investigates molecular mechanisms of cancer development and progression while developing computational approaches to analyze complex genomic datasets. A significant portion of his research focuses on translating genomic discoveries into clinical practice through biomarker development and implementation science. His work includes systematic analysis of genetic and gene regulation information in clinical cohorts as part of the Genome Data Analysis Network and clinical trials implementing genetic health screening for hereditary breast and ovarian cancer and Lynch syndromes.

Analysis of Dr. Spellman's recent publications (2024-2025) reveals a strong focus on cancer genomics, with particular emphasis on tumor evolution, liquid biopsy technologies (ctDNA and cell-free RNA), precision diagnostics, and the molecular basis of cancer progression. His work spans multiple cancer types including breast, prostate, pancreatic, and hematological malignancies, often employing cutting-edge genomic technologies and computational approaches. A notable theme across his publications is the integration of basic science discoveries with clinical applications to improve cancer diagnosis and treatment.

Dr. Spellman leads multiple research initiatives including the Genome Data Analysis Network and clinical trials implementing genetic health screening. His laboratory develops and applies genomic technologies across the translational spectrum from basic discovery to clinical implementation. His work on polygenic risk implementation and modeling represents an important frontier in precision medicine.

Dr. Spellman's research program includes population-scale studies such as the Healthy Oregon Project, which focuses on statewide cancer research and recruitment approaches for population cohorts. His work on understanding the molecular biology of cellular replication provides fundamental insights that inform his cancer research. The integration of diverse methodologies and approaches across his research program represents a comprehensive strategy to improve cancer outcomes through genomic medicine.